25Aug
Johnson & Johnson Announces Acquisition of Momenta For $6.5 Billion
Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceuticals, Inc. for $6.5 billion. The acquisition gives J&J’s Janssen unit full global rights to Momenta’s nipocalimab (M281), an anti-FcRn antibody designed to treat a number of autoantibody-driven disorders, including generalized myasthenia gravis (gMG), warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of the fetus and newborn (HDFN)....
By:
Goodwin
Related
When an employer experiences growth and is projected to employ 50 or more employees, an employer can...
Read More >
In re Oracle Corp. Derivative Litig., C.A. No. 2017-0337-SG (Del. Ch. July 9, 2020) - After investi...
Read More >
At start-up, young technology companies focus entirely on their products, want to pitch and bring VC...
Read More >
P.A.L. Environmental Safety Corp. v. North American Dismantling Corp. Et Al., No. 19-11630, 2020 BL ...
Read More >
Does the way you communicate affect whether others trust you? Much, much more than you realize. In t...
Read More >
The Washington Employment Security Department (ESD) has pushed back the first reporting deadline und...
Read More >